# Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

> **NCT03988634** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 467 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF)

## Interventions

- **DRUG:** sacubitril/valsartan
- **DRUG:** valsartan
- **DRUG:** sacubitril/valsartan matching placebo
- **DRUG:** valsartan matching placebo

## Key facts

- **NCT ID:** NCT03988634
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-29
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988634, "Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03988634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*